Drug Development
IN-HOUSE RD PROJECTS
Bio-Betters Drugs are new drugs designed from existing ones with improved properties such as higher efficacy, selectivity, stability, half-life, and/or lower toxicity/immunogenicity.
Projects
Super Agonist Antibody Platform
AgTa-101
(Bio-Better)
AgTa-106
(Bio-Better)
AgTa-234
(Bio-Better)
AgTa-203
(Bio-Better)
Diseases
(Platform)
Immune Diseases
Cardiovascular Diseases
Tumors
Liver Tumor
Current Status
Validating with AI and in vitro testing.
Optimizing the candidates with AI and validating in wet-lab.
Optimizing the candidates with AI and validating in wet-lab.
Optimizing the candidates with AI and validating in wet-lab.
Optimizing the candidates with AI and validating in wet-lab.
Projects
Super Agonist
Antibody Platform
AgTa-279 (Bio-Better)1
AgTa-301 (Bio-Better)
AgTa-101 (Bio-Better)
AgTa-234 (Bio-Better)
AgTa-203 (Bio-Better)
Diseases
(Platform)
Rheumatoid Arthritis
Fibrosis
IBD （UC & Crohn’s）
Tumors
Liver Tumor
Current Status
Validating with AI and In-Vitro testing.
Selecting the best candidates with AI and testing in vitro/vivo disease models
Selecting the best candidates with AI and testing in vitro/vivo disease models
Selecting the best candidates with AI and testing in vitro/vivo disease models
Screening candidates with AI and testing in vitro/vivo disease models.
Screening candidates with AI and testing in vitro/vivo disease models.
Estimated Completion Date
Q1 2025
Q4 2025
Q4 2025
Q1 2026
Q2 2026
Q2 2026
